SK Biopharmaceuticals' Xcopri: How This Epilepsy Drug Surged 26.4% in U.S. Sales in 2026
AI 요약 정보
- SK Biopharmaceuticals' Xcopri Q3 U.S. sales: 223.6 billion KRW
- Xcopri averages 50,644 U.S. monthly prescriptions, up 22.5%
- Nine-month U.S. sales reach 645.7 billion KRW, up 40.5%
